Request Here
Subscribe here
ELZA’s Julia Schinzel wins the SBAO Award for best undergraduate thesis from the Swiss Board of Optometrists, along with course-mate Alice Christen. The optometrists’ thesis
Photoactivated chromophore for keratitis-corneal cross-linking (PACK-CXL) has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
The ELZA Institute had a strong presence at the 82nd SBAO annual congress in Bern. Prof. Kaweh Mansouri, Dr. Emilio Torres-Netto and Ms. Julia Schinzel all
Shaopei Wang et al. wanted to know who are the current “big hitters” in corneal cross-linking (CXL) research, so they performed and published a literature
Professor Farhad Hafezi from the ELZA Institute has prepared a presentation that provides a comprehensive overview of how oxygen concentration is at the center of all these decisions. CXL and oxygen is at the center of everything to do with the UV-riboflavin cross-linking reaction
Dr. Sebastian Siebelman from the media outlet, “Digital Ophthalmology” interviews ELZA AG’s Chief Executive Officer, Nikki Hafezi, as part of their “Visionaries” series. Several topics
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Prof. Hafezi, Medical Director of the ELZA Institute in Dietikon, Zurich, Switzerland, co-authored a recently published paper that indicated that obese adults have a lower
